Bordini C A, Arruda M A, Ciciarelli M C, Speciali J G
Departamento de Neurologia, Faculdade de Medicina de Ribeirão Preto (FMRP), Universidade de São Paulo (USP), Brasil.
Arq Neuropsiquiatr. 1997 Sep;55(3B):536-41. doi: 10.1590/s0004-282x1997000400003.
Fourty-five migraine without aura patients underwent a parallel double-blind trial aiming the comparison of the effects of propranolol 60 mg/day to flunarizine 10 mg/day and to propranolol 60 mg/day plus flunarizine 10 mg/day simultaneously. There were 3 groups, each one with 15 patients. After a 20-day-baseline period, each group received one kind of treatment during 120 days. Migraine index on propranolol was 23.4*, on flunarizine 18.7* and on both drugs 14.4*, mean frequency of attacks on propranolol was 1.26**, on flunarizine 1.2** and on both drugs 1.13** (*p < 0.05, **p < 0.01 compared to baseline) and global evaluation was reduced with all forms of treatment. It was not found statistical differences between groups, nevertheless there was a trend in the group using two drugs reaching lower values in migraine index, frequency of attacks and global evaluation. In individuals using flunarizine (alone or associated with propranolol) the therapeutic effect was largely maintained up to 45 days after drug withdrawal.
45例无先兆偏头痛患者进行了一项平行双盲试验，旨在比较每日60毫克普萘洛尔、每日10毫克氟桂利嗪以及每日60毫克普萘洛尔加每日10毫克氟桂利嗪同时使用的效果。试验分为3组，每组15例患者。在20天的基线期后，每组在120天内接受一种治疗。普萘洛尔组的偏头痛指数为23.4*，氟桂利嗪组为18.7*，两种药物联合组为14.4*，普萘洛尔组的平均发作频率为1.26**，氟桂利嗪组为1.2**，两种药物联合组为1.13**（*与基线相比，p<0.05；**与基线相比，p<0.01），所有治疗方式的整体评估均有所降低。未发现组间存在统计学差异，不过在使用两种药物的组中，偏头痛指数、发作频率和整体评估有达到更低值的趋势。在使用氟桂利嗪的个体（单独使用或与普萘洛尔联合使用）中，停药后长达45天治疗效果仍基本维持。
